Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?

The weight loss drug market is growing rapidly.Eli Lilly (LLY 0.67%) shares have soared more than 87% over the past year, making this player look more like a growth stock than a slower-paced but steady pharmaceutical stock. Lilly sells a broad range of medicines, but what lately has struck the fancy of investors -- and doctors and patients -- is the company's weight loss portfolio.Doctors prescribe Lilly's Mounjaro and Zepbound to help patients manage their weight, and the results have been fantastic. This ...